PMID- 16714073
OWN - NLM
STAT- MEDLINE
DCOM- 20060816
LR  - 20181113
IS  - 0264-410X (Print)
IS  - 0264-410X (Linking)
VI  - 24
IP  - 25
DP  - 2006 Jun 19
TI  - Importance of HLA-DQ and HLA-DP polymorphisms in cytokine responses to naturally 
      processed HLA-DR-derived measles virus peptides.
PG  - 5381-9
AB  - We studied the association between class II human leukocyte antigen 
      (HLA)-DRB1*0301 presented measles virus (MV) peptide-specific cytokine responses 
      and DQB1 and DPB1 alleles among 313 individuals who received two doses of 
      measles-mumps-rubella-II vaccine. The overall median IFN-gamma secretion levels 
      (first and third quartiles) for the 19-amino acid MV phosphoprotein (MV-P)- and 
      14-amino acid MV nucleoprotein (MV-N)-derived peptides were 27.7 pg/ml (1.8, 
      109.4) and 1.9 pg/ml (-6.2, 13.0), respectively; median IL-4 secretion levels 
      were -0.6 pg/ml (-7.1, 6.2) and 2.4 pg/ml (-3.2, 9.3), respectively. Primary 
      statistical analyses were adjusted for previously identified DRB1 associations. A 
      marginally significant increase in the frequency of the DQB1*0604 (p=0.02) allele 
      was found among subjects who demonstrated detectable IL-4 levels to the MV-P 
      peptide. Further, DPB1*0201 (p=0.02) and DPB1*1301 (p=0.09) alleles provided 
      suggestive evidence of an association with MV-P-induced IL-4 secretion. 
      Examination of IFN-gamma responses to MV-P and MV-N indicated that none of the 
      individual alleles of the DQB1 and DPB1 loci were associated with peptide-induced 
      T cell response. An increase in the frequency of DPB1*0501 (p=0.01) was found 
      among subjects who failed to produce MV-N peptide-specific IL-4 responses. These 
      data further confirm that HLA-DRB1 alleles are the major restriction molecules 
      for MV-P and MV-N measles virus antigen presentation to T cells. We speculate 
      that MV-P and MV-N peptides derived from DRB1*0301 could potentially be 
      recognized in association with different HLA molecules, including DQB1 and DPB1; 
      however, statistical adjustments for the effect of HLA-DR locus could potentially 
      alter these genetic relationships. This concept provides important information 
      supporting the use of promiscuous peptides in a peptide-based vaccine approach.
FAU - Ovsyannikova, Inna G
AU  - Ovsyannikova IG
AD  - Mayo Vaccine Research Group, Guggenheim 611C, 200 First Street SW, Rochester, MN 
      55905, USA.
FAU - Vierkant, Robert A
AU  - Vierkant RA
FAU - Poland, Gregory A
AU  - Poland GA
LA  - eng
GR  - R03 AI053592/AI/NIAID NIH HHS/United States
GR  - AI 53592/AI/NIAID NIH HHS/United States
GR  - R01 AI033144/AI/NIAID NIH HHS/United States
GR  - R01 AI048793/AI/NIAID NIH HHS/United States
GR  - R37 AI048793/AI/NIAID NIH HHS/United States
GR  - AI 48793/AI/NIAID NIH HHS/United States
GR  - AI 33144/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20060503
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Cytokines)
RN  - 0 (HLA-DP Antigens)
RN  - 0 (HLA-DQ Antigens)
RN  - 0 (HLA-DQ beta-Chains)
RN  - 0 (HLA-DQB1 antigen)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (HLA-DRB1*03:01 antigen)
RN  - 0 (Measles-Mumps-Rubella Vaccine)
RN  - 0 (Peptides)
RN  - 207137-56-2 (Interleukin-4)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Adolescent
MH  - Alleles
MH  - Amino Acid Sequence
MH  - Child
MH  - Cytokines/*metabolism
MH  - Female
MH  - HLA-DP Antigens/*genetics
MH  - HLA-DQ Antigens/*genetics
MH  - HLA-DQ beta-Chains
MH  - HLA-DR Antigens/chemistry/genetics/metabolism
MH  - HLA-DRB1 Chains
MH  - Humans
MH  - Interferon-gamma/metabolism
MH  - Interleukin-4/metabolism
MH  - Male
MH  - Measles virus/chemistry/*immunology
MH  - Measles-Mumps-Rubella Vaccine/administration & dosage/immunology
MH  - Molecular Sequence Data
MH  - Peptides/chemistry/*immunology/metabolism
MH  - *Polymorphism, Genetic
PMC - PMC1853367
MID - NIHMS20085
EDAT- 2006/05/23 09:00
MHDA- 2006/08/17 09:00
PMCR- 2008/02/03
CRDT- 2006/05/23 09:00
PHST- 2006/04/24 00:00 [received]
PHST- 2006/04/25 00:00 [accepted]
PHST- 2006/05/23 09:00 [pubmed]
PHST- 2006/08/17 09:00 [medline]
PHST- 2006/05/23 09:00 [entrez]
PHST- 2008/02/03 00:00 [pmc-release]
AID - S0264-410X(06)00486-5 [pii]
AID - 10.1016/j.vaccine.2006.04.034 [doi]
PST - ppublish
SO  - Vaccine. 2006 Jun 19;24(25):5381-9. doi: 10.1016/j.vaccine.2006.04.034. Epub 2006 
      May 3.